Literature DB >> 8168072

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

F Jänicke1, L Pache, M Schmitt, K Ulm, C Thomssen, A Prechtl, H Graeff.   

Abstract

The serine protease urokinase-type plasminogen activator (uPA) plays a key role in tumor-associated proteolysis in malignant solid tumors. Proteolytic activity of uPA is controlled by its naturally occurring plasminogen activator inhibitor type 1. As an initial observation, a correlation of enzymatic uPA activity in breast cancer cytosols with prognosis was described in 1988 (Duffy et al., Cancer (Phila.), 62: 531-533, 1988). A pronounced prognostic impact of uPA, independent of classical risk parameters, was then first demonstrated in detergent-extracted (Triton X-100) breast cancer tissues by applying enzyme-linked immunosorbent assay techniques (Jänicke et al., Lancet, 2: 1049, 1989; Fibrinolysis, 4:69-78, 1990; Duffy et al., Cancer Res., 50: 6827-6829, 1990). In addition, not only uPA but also plasminogen activator inhibitor type 1 were shown to be of prognostic value in breast cancer (Jänicke et al., Semin. Thromb. Hemostasis, 17: 303-312, 1991; Breast Cancer Res. Treat., 24: 195-208, 1993). Subsequently, the prognostic value of uPA and plasminogen activator inhibitor type 1 was also confirmed in studies using archived "cytosol fractions" of breast cancer tissues (Foekens et al., Cancer Res., 52: 6101-6105, 1992; Spyratos et al., J. Natl. Cancer Inst., 84: 1266-1272, 1992; Grondahl-Hansen et al., Cancer Res., 53: 2513-2521, 1993; Sumiyoshi et al., Int. J. Cancer, 50: 345-348, 1992). A direct comparison of both methods with regard to prognosis, however, was lacking. We therefore prepared both the detergent-treated tissue extracts and the cytosol fractions from the same breast cancer specimens to allow a direct comparison of both methods. In 247 breast cancer patients investigated, the Triton X-100-extracted tissues revealed about twice as much uPA antigen (uPATx: median, 2.32 ng/mg protein) than the cytosol fractions (uPAcyt: median, 1.07 ng/mg protein). In contrast, the presence of Triton X-100 did not result in an increase of PAI-1 (PAI-1Tx: median, 6.34 ng PAI-1/mg protein) compared to the cytosol fractions (PAI-1cyt: median, 7.15 ng PAI-1/mg protein). Good correlations between uPATx and uPAcyt (R = 0.72) and between PAI-1Tx and PAI-1cyt (R = 0.88) were observed. Furthermore, PAI-1 and uPA are moderately correlated with each other (uPATx versus PAI-1Tx: R = 0.40; uPAcyt versus PAI-1cyt: R = 0.39). The prognostic power of uPA showed its best advantage in Triton X-100-extracted tissues (RR = 3.22), most pronounced in the subgroups of node-negative and premenopausal patients, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168072

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.

Authors:  Lori J Goldstein
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

2.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

3.  Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.

Authors:  Gordana Horvatić Herceg; Davorin Herceg; Marko Kralik; Zdenka Bence-Zigman; Hrvojka Tomić-Brzac; Ana Kulić
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

4.  Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer.

Authors:  Christine Schröder; Isabell Witzel; Volkmar Müller; Sylke Krenkel; Ralph M Wirtz; Fritz Jänicke; Udo Schumacher; Karin Milde-Langosch
Journal:  J Cancer Res Clin Oncol       Date:  2011-05-18       Impact factor: 4.553

5.  Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases.

Authors:  John Akudugu; Antonio Serafin; Lothar Böhm
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-17       Impact factor: 4.553

6.  uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer.

Authors:  Lothar Böhm; Antonio Serafin; John Akudugu; Pedro Fernandez; Andre van der Merwe; Naseem A Aziz
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

Review 7.  Biomolecular features of clinical relevance in breast cancer.

Authors:  Maria Grazia Daidone; Angelo Paradiso; Massimo Gion; Nadia Harbeck; Fred Sweep; Manfred Schmitt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-17       Impact factor: 9.236

8.  Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Authors:  Matthias Kotzsch; Thomas Kirchner; Susanne Soelch; Sonja Schäfer; Katrin Friedrich; Gustavo Baretton; Viktor Magdolen; Thomas Luther
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

9.  Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow.

Authors:  Bahriye Aktas; Agnes Bankfalvi; Martin Heubner; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Mol Clin Oncol       Date:  2013-09-02

10.  Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Authors:  H Taubert; P Würl; T Greither; M Kappler; M Bache; C Lautenschläger; S Füssel; A Meye; A W Eckert; H-J Holzhausen; V Magdolen; M Kotzsch
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.